{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016374","form_type":"8-K","ticker":"NEPH","cik":"0001196298","company_name":"NEPHROS INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.168914+00:00","generated_at":"2026-06-15T03:38:08.877021+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nephros appoints Robert Banks as President & CEO; Andy Astor remains interim CFO","bullets":["Robert Banks named President & CEO effective after Q1 2023 10-Q filing; also appointed to Board.","Andy Astor resigns as President & CEO but stays as interim CFO and advisor; departure not due to disagreement.","Banks receives $350K base salary, potential increases to $400K/$450K at $15M/$20M revenue milestones.","Banks granted 357,165 stock options at $1.44 per share, vesting over 4 years.","Company highlights 40% YoY base revenue growth and early cash-flow breakeven in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016374","json":"https://secwatch.observer/filing/0001493152-23-016374.json","markdown":"https://secwatch.observer/filing/0001493152-23-016374.md","text":"https://secwatch.observer/filing/0001493152-23-016374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1196298/000149315223016374/0001493152-23-016374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1196298/000149315223016374/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:38:08.877021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2eab2fd04e","claim":"Robert Banks was appointed as Director at NEPHROS INC.","evidence_excerpt":"Mr. Banks was also appointed to the Company’s Board of Directors as a Class III director as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315223016374/0001493152-23-016374-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"49c5b6cfe3","claim":"Robert Banks was appointed as President and Chief Executive Officer at NEPHROS INC.","evidence_excerpt":"On May 5, 2023, Nephros, Inc. (the “Company”) entered into an employment agreement with Robert Banks (the “Employment Agreement”) pursuant to which the Company appointed Mr. Banks as its President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315223016374/0001493152-23-016374-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ff75454573","claim":"Andrew Astor resigned as President and Chief Executive Officer at NEPHROS INC.","evidence_excerpt":"On May 5, 2023, Andrew Astor resigned as the Company’s President and Chief Executive Officer and from the Company’s Board of Directors, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315223016374/0001493152-23-016374-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}